Inflammasome

Inflammasome Inhibitors?

lnflammasomes are intracellular multiprotein complex in the innate immune system, the body's first line of defense against pathogen-associated molecular patterns (PAMPs) or host-derived cellular stress signals known as damage-associated molecular patterns (DAMPs). Once activated, inflammasomes produce highly proinflammatory cytokines such as IL-1β and IL-18 and induce programed cell death called pyroptosis. Dysregulation of inflammasomes is associated with a vast number of autoimmune and inflammatory disorders.

Novel mechanism of Shaperon/Hudson's Inflammasome Inhibitors

Unlike other inflammasome inhibitors which target to inhibit only the activation phase of inflammasome, Shaperon/Hudson's GPCR19-P2X7 modulation yields multiple advantages over conventional approaches.

Suppresses both priming and activation phase of inflammasome pathway, resulting in the suppression of multiple cytokines and chemokines including ll-1β, TNF-α, IL-6, IL-18, etc.
Acts selectively on inflammatory immune cells
Efficacy variation less likely (GPCR19 is non-polymorphic)
Targeting GPCR19, top regulator of inflammasome activation, avoids NLRP3-associated redundant pathways such as NLRP1, NLRC4, AIM2

Inflammasome

Inflammasome Inhibitors?

Novel mechanism of Shaperon/Hudson's Inflammasome Inhibitors

This website uses cookies.